Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

unknown125%
completed250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Health Evaluation in African Americans Using RAS Therapy

NCT02471833
terminatedphase_2

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

NCT04360551
unknownphase_4

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

NCT03550859
completed

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

NCT01050062

Clinical Trials (4)

Showing 4 of 4 trials
NCT02471833Phase 1

Health Evaluation in African Americans Using RAS Therapy

Completed
NCT04360551Phase 2

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

Terminated
NCT03550859Phase 4

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Unknown
NCT01050062

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4